GlassScriptPhysician profile
Katelyn Lamer
NPI 1922474865
$7,820.97
in general payments reported to CMS, 2019-2025
20 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,288 · 2022: $1,206 · 2023: $1,560 · 2024: $1,596 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,322 · Education: $3.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,322.30 |
| Education | $3.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,394.14 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $880.22 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $817.90 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $811.96 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $758.22 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $586.15 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $530.98 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $302.89 | 2021-2022 | |
| Lundbeck LLC | $278.19 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $138.40 | 2025 | Cobenfy |
| Corium, LLC | $110.70 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $41.09 | 2021-2023 | Trintellix |
| Sage Therapeutics, LLC | $36.04 | 2024-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $31.87 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $23.18 | 2024 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.37 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $16.24 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $14.40 | 2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $13.23 | 2023 | Jornay Pm |
| Eisai INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Lamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.